Amedisys Inc (AMED)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -9,747 | 2,648 | 2,330 | 112,184 | 118,609 | 120,939 | 140,303 | 190,873 | 209,072 | 220,125 | 247,100 | 201,625 | 183,557 | 166,157 | 128,276 | 127,302 | 126,800 | 126,600 | 123,900 | 123,500 |
| Total stockholders’ equity | US$ in thousands | 1,066,510 | 1,039,910 | 1,006,780 | 1,079,120 | 1,051,570 | 1,015,740 | 985,646 | 966,758 | 931,351 | 905,264 | 874,272 | 788,153 | 809,224 | 756,205 | 720,851 | 679,197 | 640,450 | 602,564 | 561,781 | 520,246 |
| ROE | -0.91% | 0.25% | 0.23% | 10.40% | 11.28% | 11.91% | 14.23% | 19.74% | 22.45% | 24.32% | 28.26% | 25.58% | 22.68% | 21.97% | 17.80% | 18.74% | 19.80% | 21.01% | 22.05% | 23.74% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-9,747K ÷ $1,066,510K
= -0.91%
Amedisys Inc.'s return on equity (ROE) has shown a decreasing trend over the past few quarters. In Q4 2023, the ROE was negative at -0.91%, indicating that the company's net income was insufficient to cover shareholders' equity. This was a significant drop from the previous quarter's positive ROE of 0.25%.
Compared to the same quarter the previous year, there has been a substantial decline in ROE. In Q4 2022, the ROE was 11.28%, indicating a steep decrease to the negative territory in Q4 2023.
The ROE for Amedisys Inc. in Q2 and Q3 2022 was relatively higher at 14.23% and 11.91% respectively, showing a more favorable performance compared to the recent quarters. However, the ROE has been on a declining trend since then.
Overall, the negative ROE in Q4 2023 raises concerns about the company's profitability and efficiency in generating returns for its shareholders. Amedisys Inc. may need to focus on improving its earnings and cost management to enhance its ROE performance in the future.
Peer comparison
Dec 31, 2023